X-Box Binding Protein-1 in Breast Cancer

Abstract

Antiestrogens are effective in premenopausal and postmenopausal patients, and in the chemopreventive, adjuvant and metastatic settings (5), probably through the induction of growth arrest/apoptosis (5). The triphenylethylene TAM, a partial agonist, is the most widely used anti estrogen. Long term TAM use reduces the incidence of contralateral breast cancer (antagonist) and primary breast cancer in high risk women (antagonist), maintains bone density (agonist) and increases the risk of endometrial carcinomas (agonist) (10). Newer antiestrogens include the "pure antagonist" ICI 182,780 (no agonist activity). In patients that had previously shown a response to TAM but recurred, ICI 182,780 produces a response rate significantly higher than the response rate for crossover to another triphenylethylene (Toremifene) following TAM failure (29).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2003
Accession Number
ADA421992

Entities

People

  • Robert R. Clarke

Organizations

  • Georgetown University

Tags

DTIC Thesaurus Topics

  • Breast Cancer
  • Cell Physiological Processes
  • Chemistry
  • Health Services
  • Medical Personnel
  • Proteins

Readers

  • Breast cancer cell signaling and growth regulation.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech